CRIS Current Research Information System

PAOLINI, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.059
AS - Asia 8.948
EU - Europa 8.711
AF - Africa 791
SA - Sud America 513
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 16
Totale 29.059
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.952
CN - Cina 2.837
SG - Singapore 2.669
GB - Regno Unito 2.590
SE - Svezia 1.535
VN - Vietnam 1.513
IT - Italia 1.071
DE - Germania 1.067
IN - India 547
HK - Hong Kong 545
RU - Federazione Russa 456
BR - Brasile 375
FR - Francia 336
IE - Irlanda 297
NL - Olanda 278
KR - Corea 265
UA - Ucraina 214
ZA - Sudafrica 205
TG - Togo 182
JP - Giappone 156
EE - Estonia 154
GR - Grecia 148
CI - Costa d'Avorio 135
SC - Seychelles 131
CH - Svizzera 117
NG - Nigeria 112
FI - Finlandia 109
JO - Giordania 93
BG - Bulgaria 87
IR - Iran 81
CA - Canada 72
AR - Argentina 68
BE - Belgio 51
PL - Polonia 45
ES - Italia 42
TR - Turchia 42
ID - Indonesia 40
AT - Austria 37
BD - Bangladesh 29
MX - Messico 27
PH - Filippine 20
EC - Ecuador 19
EU - Europa 19
UZ - Uzbekistan 19
HR - Croazia 16
AU - Australia 15
PY - Paraguay 15
IQ - Iraq 13
LB - Libano 12
LT - Lituania 12
MY - Malesia 11
CL - Cile 10
RO - Romania 10
CO - Colombia 9
PK - Pakistan 8
AE - Emirati Arabi Uniti 7
CZ - Repubblica Ceca 7
KG - Kirghizistan 7
PE - Perù 7
MK - Macedonia 6
DZ - Algeria 5
EG - Egitto 5
KZ - Kazakistan 5
QA - Qatar 5
RS - Serbia 5
TN - Tunisia 5
TW - Taiwan 5
VE - Venezuela 5
MA - Marocco 4
PT - Portogallo 4
AL - Albania 3
BA - Bosnia-Erzegovina 3
IL - Israele 3
LU - Lussemburgo 3
LV - Lettonia 3
SA - Arabia Saudita 3
AZ - Azerbaigian 2
GY - Guiana 2
KE - Kenya 2
NP - Nepal 2
PA - Panama 2
TM - Turkmenistan 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CR - Costa Rica 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GE - Georgia 1
HN - Honduras 1
HU - Ungheria 1
JM - Giamaica 1
KW - Kuwait 1
LI - Liechtenstein 1
LK - Sri Lanka 1
MD - Moldavia 1
ML - Mali 1
Totale 29.049
Salva come PNG Salva come JPEG
Città #
Southend 2.395
Singapore 1.777
Ashburn 1.059
Chandler 942
Fairfield 924
Dong Ket 720
Hefei 625
Hong Kong 540
Houston 525
Wilmington 519
Woodbridge 451
Ann Arbor 428
Seattle 421
Princeton 407
Beijing 393
Santa Clara 376
Cambridge 336
Dublin 296
Boardman 277
Seoul 237
Westminster 210
Nanjing 203
Bologna 184
Padova 183
Lomé 182
Abidjan 135
New York 135
Medford 132
Los Angeles 123
Tokyo 110
Hanoi 103
Ho Chi Minh City 101
Jinan 98
Shenyang 98
Bern 95
Saint Petersburg 95
Amman 93
Dallas 89
Milan 86
Helsinki 85
Sofia 85
Berlin 84
Jacksonville 83
Buffalo 80
Hebei 78
Abeokuta 72
Nanchang 72
Redondo Beach 70
Munich 66
Frankfurt am Main 64
Turin 63
Changsha 59
Bremen 58
Bengaluru 55
San Diego 55
Redwood City 53
Tianjin 51
Brussels 50
Florence 50
São Paulo 50
Zhengzhou 47
Guangzhou 44
Jiaxing 43
Rome 39
Falls Church 33
Shanghai 33
Haikou 32
Redmond 32
Athens 30
Mülheim 30
Norwalk 28
Hangzhou 27
Ningbo 26
Taiyuan 26
Istanbul 25
San Jose 25
Tongling 25
Grafing 24
London 24
Mahé 24
Falkenstein 23
Kunming 23
Paris 23
Taizhou 23
Warsaw 23
Chicago 22
Mountain View 22
Toronto 22
North York 21
Vienna 21
Phoenix 20
Yubileyny 20
Jakarta 19
Wuhan 19
Davao City 18
Tehran 18
Amsterdam 17
Brooklyn 17
Des Moines 17
Hyderabad 17
Totale 18.508
Salva come PNG Salva come JPEG
Nome #
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 321
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 317
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 315
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 306
A HIGH SENSITIVE NANOFLUIDIC ARRAY IMPROVES THE DETECTION OF RARE COPIES OF BCR-ABL1 TRANSCRIPT IN PATIENTS WITH PHILADELPHIA POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 288
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 280
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 266
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 255
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 243
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 240
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 239
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 237
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 228
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 226
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 222
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 219
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 216
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes 213
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. 213
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 212
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients 208
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 206
WHOLE TRANSCRIPTOME DEEP-SEQUENCING IDENTIFIES NOVEL POINT MUTATIONS, GENE EXPRESSION AND ALTERNATIVE SPLICING PROFILES IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 204
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 204
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 202
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 201
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF BY GENOMIC DELETIONS IS A FREQUENT EVENT IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS AND CONTRIBUTES TO DISEASE PROGRESSION 198
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 197
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide 196
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 196
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 194
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 193
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 190
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 190
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 187
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 185
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. 184
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 183
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 183
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF IS FREQUENTLY DELETED BUT NOT MUTATED IN BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 183
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 181
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 181
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 176
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 176
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 176
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 174
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 174
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 171
FROM DIAGNOSIS TO RELAPSE: AN HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING ANALYSIS OF PAIRED DIAGNOSIS-RELAPSE SAMPLES IN BCR-ABL1-POSITIVE ALL INDICATES INVOLVEMENT OF ALTERATIONS TARGETING KEY REGULATORS OF TUMOR SUPPRESSION, CELL CYCLE CONTROL, AND LYMPHOID/B CELL DEVELOPMENT 170
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 170
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 169
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 169
Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. 166
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 164
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 164
Increased angiogenesis seems to correlate with inferior overall survival in myeloid sarcoma patients 163
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 162
SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis. 161
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 160
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 159
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 158
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 157
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 156
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 156
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL 156
EFFICACY AND FEASIBILITY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): A SINGLE-CENTER EXPERIENCE 156
Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: a diagnostic and therapeutic challenge. 155
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 154
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 154
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 154
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 153
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 152
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 152
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 152
Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study 151
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 151
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 150
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 148
Saprochaete clavata infections in patients undergoing treatment for haematological malignancies: A report of a monocentric outbreak and review of the literature 148
Blastic plasmacytoid dendritic cell neoplasm: is it time to redefine the standard of care? 147
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 147
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 146
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 145
The PAX5gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemiabut is not associated with outcome. A report on behalf of the GIMEMA AcuteLeukemia Working Party 144
TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia 144
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up 143
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 141
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia. 140
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 139
THE RS564398, A POLYMORPHISM IN “THE ANTISENSE NON-CODING RNA IN THE INK4 LOCUS”, ANRIL, IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) SUSCEPTIBILITY 139
Successful treatment of disseminated Fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B 138
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 138
Pediatric-Like Intensified Therapy In Adult Acute Lymphoblastic Leukemia: A Single Centre Experience 136
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 136
SNP array reveals a new deletion of JAK2 in AML patients 133
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study. 132
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 132
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 132
Indoleamine 2,3-Dioxygenase (IDO) Is Associated with High Incidence of Chemorefractory Disease in Acute Myeloid Leukemia (AML) Patients 132
IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients. 132
Totale 18.155
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.320
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.320
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.980 0 0 0 0 0 0 53 199 301 124 102 1.201
2021/20224.285 463 82 275 431 413 288 71 273 209 331 736 713
2022/20234.321 490 673 227 546 347 326 149 260 690 83 333 197
2023/20241.192 54 194 52 130 85 256 74 65 56 69 88 69
2024/20254.433 192 694 366 299 611 224 401 124 49 373 246 854
2025/20265.439 894 1.124 943 769 1.156 549 4 0 0 0 0 0
Totale 29.637